Volume 14, Issue 1 (Winter 2025)
aumj 2025, 14(1): 59-81 |
Back to browse issues page
Ethics code: IR.IAU.TEH.REC.1401.110
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mirzaie A, Abbasi M. Design, synthesis and formulation of niosomes containing acetaminophen: structural properties, anticancer effects and apoptotic gene expression analysis. aumj 2025; 14 (1) :59-81
URL: http://aums.abzums.ac.ir/article-1-1786-en.html
URL: http://aums.abzums.ac.ir/article-1-1786-en.html
1- Department of Biology, Parand Branch, Islamic Azad University, Parand, Iran
2- Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran ,Bio_mar.abbasi@yahoo.com
2- Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran ,
Abstract: (808 Views)
Background: Niosomes are innovative targeted drug delivery systems that enhance the biological properties of drugs. This study aimed to synthesize acetaminophen-containing niosomes, investigate their structural characteristics, assess cytotoxicity, and analyze the expression of apoptotic genes.
Materials and Methods: In this experimental study, various formulations of acetaminophen-loaded niosomes were synthesized. Their structural characteristics were examined using scanning electron microscopy (SEM), dynamic light scattering (DLS), and Fourier transform infrared spectroscopy (FTIR). The cytotoxic effects on the colon cancer cell line (HT29) were assessed via the MTT colorimetric method. Additionally, the expression levels of apoptotic genes Bax and Bcl2 were evaluated.
Results: The synthesis results indicated that the Nio1 formulation was the optimal variant, exhibiting a size of 289.6 nm. FTIR analysis confirmed successful niosome synthesis. Drug release tests revealed that the release rate of acetaminophen in niosome form was significantly slower than that of the free drug, with only 28% released over 8 hours. Furthermore, niosomes containing acetaminophen demonstrated significant cytotoxic effects against the HT29 cell line. The expression of the apoptotic gene Bax increased significantly by 2.14±0.34 (P<0.01), while the expression of Bcl2 decreased by 0.46±0.11 (P<0.01).
Conclusion: The findings of this study indicate that acetaminophen-loaded niosomes exhibit significant cytotoxic effects against the HT29 cell line and enhance the expression of apoptotic genes. These results suggest that niosomes could be a promising drug delivery system, warranting further research to optimize their application in cancer treatment.
Materials and Methods: In this experimental study, various formulations of acetaminophen-loaded niosomes were synthesized. Their structural characteristics were examined using scanning electron microscopy (SEM), dynamic light scattering (DLS), and Fourier transform infrared spectroscopy (FTIR). The cytotoxic effects on the colon cancer cell line (HT29) were assessed via the MTT colorimetric method. Additionally, the expression levels of apoptotic genes Bax and Bcl2 were evaluated.
Results: The synthesis results indicated that the Nio1 formulation was the optimal variant, exhibiting a size of 289.6 nm. FTIR analysis confirmed successful niosome synthesis. Drug release tests revealed that the release rate of acetaminophen in niosome form was significantly slower than that of the free drug, with only 28% released over 8 hours. Furthermore, niosomes containing acetaminophen demonstrated significant cytotoxic effects against the HT29 cell line. The expression of the apoptotic gene Bax increased significantly by 2.14±0.34 (P<0.01), while the expression of Bcl2 decreased by 0.46±0.11 (P<0.01).
Conclusion: The findings of this study indicate that acetaminophen-loaded niosomes exhibit significant cytotoxic effects against the HT29 cell line and enhance the expression of apoptotic genes. These results suggest that niosomes could be a promising drug delivery system, warranting further research to optimize their application in cancer treatment.
Type of Study: Research |
Subject:
General
Received: 2024/03/04 | Accepted: 2024/06/01 | Published: 2024/12/30
Received: 2024/03/04 | Accepted: 2024/06/01 | Published: 2024/12/30
References
1. WHO Cancer. [(accessed on 14 July 2021)]. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer
2. Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. Global Cancer Observatory: Cancer Today. [(accessed on 14 July 2021)]. Available online:
3. Papamichael D., Audisio R.A., Glimelius B., de Gramont A., Glynne-Jones R., Haller D., Kohne C.H., Rostoft S., Lemmens V., Mitry E., et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015;26:463-476. [DOI:10.1093/annonc/mdu253] [PMID]
4. Triantafillidis J.K., Nasioulas G., Kosmidis P.A. Colorectal cancer and inflammatory bowel disease: Epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009;29:2727-2737.
5. Edwards B.K., Ward E., Kohler B.A., Eheman C., Zauber A.G., Anderson R.N., Jemal A., Schymura M.J., Lansdorp-Vogelaar I., Seeff L.C., et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573. [DOI:10.1002/cncr.24760] [PMID] []
6. Navarro M., Nicolas A., Ferrandez A., Lanas A. Colorectal cancer population screening programs worldwide in 2016: An update. World J. Gastroenterol. 2017;23:3632-3642. [DOI:10.3748/wjg.v23.i20.3632] [PMID] []
7. Wilson J.M., Jungner Y.G. Principles and practice of mass screening for disease. Bol. Oficina Sanit. Panam. 1968;65:281-393.
8. Neuwelt AJ, Wu YJ, Knap N, Losin M, Neuwelt EA, Pagel MA, Warmann S, Fuchs J, Czauderna P, Wozniak M. Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Neoplasia. 2009;11:1003-1011. [DOI:10.1593/neo.09688] [PMID] []
9. Kobrinsky NL, Hartfield D, Horner H, Maksymiuk A, Minuk GY, White DF, Feldstein TJ. Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue. Cancer Invest. 1996;14:202-210. [DOI:10.3109/07357909609012140] [PMID]
10. Wu YJ, Neuwelt AJ, Muldoon LL, Neuwelt EA. Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma. Anticancer Res. 2013;33:2391-2400.
11. Allen TM. Liposomal drug formulations: Rationale for development and what we can expect for the future. Drugs. 1998;56:747-56. [DOI:10.2165/00003495-199856050-00001] [PMID]
12. Malhotra M, Jain NK. Niosomes as drug carriers. Indian Drugs. 1994;31:81-6.
13. Udupa N. Niosomes as drug carriers. In: Jain NK, editor. Controlled and novel drug delivery. 1st edition. New Delhi: CBS Publishers and Distributors; 2002.
14. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The Preparation and propereties of Niosomes-Non ionic surfactant vesicles. J Pharm Pharmacol. 1985;37:863-8. [DOI:10.1111/j.2042-7158.1985.tb04990.x] [PMID]
15. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: An overview. Int J Pharm. 2004;269:1-14. [DOI:10.1016/j.ijpharm.2003.09.016] [PMID]
16. Hu C, Rhodes DG. Proniosomes: A Novel Drug Carrier Preparation. Int J Pharm. 1999;185:23-35. [DOI:10.1016/S0378-5173(99)00122-2] [PMID]
17. Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (noisome) entrapment on the absorption and distribution of methoterxate in mice. J Pharm Pharmacol. 1985;37:237-42. [DOI:10.1111/j.2042-7158.1985.tb05051.x] [PMID]
18. Szoka F, Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes) Annu Rev Biophys Bioeng. 1980;9:467-508. [PubMed] [Google Scholar] [DOI:10.1146/annurev.bb.09.060180.002343] [PMID]
19. Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech. 2009;10:1186-92. [DOI:10.1208/s12249-009-9325-z] [PMID] []
20. Sheena IP, Singh UV, Kamath R, Uma Devi P, Udupa N. Niosomal withaferin A, with better tumor efficiency. Indian J Pharm Sci. 1998;60:45-8.
21. Baillie AJ, Coombs GH, Dolan TF, Laurie J. Non-ionic surfactant vesicles, niosomes, as delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol. 1986;38:502-5. [DOI:10.1111/j.2042-7158.1986.tb04623.x] [PMID]
22. Gregoriadis G. Targeting of drugs: Implications in medicine. Lancet. 1981;2:241-6. [DOI:10.1016/S0140-6736(81)90486-4] [PMID]
23. Morson B.C. The evolution of colorectal carcinoma. Clin. Radiol. 1984;35:425-431. [DOI:10.1016/S0009-9260(84)80033-1] [PMID]
24. Zoetemelk M., Ramzy G.M., Rausch M., Nowak-Sliwinska P. Drug-drug interactions of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin and its activity in colorectal carcinoma treatment. Molecules. 2020;25:2614. doi: 10.3390/molecules25112614. [DOI:10.3390/molecules25112614] [PMID] []
25. Petrelli F., Coinu A., Ghilardi M., Cabiddu M., Zaniboni A., Barni S. Efficacy of oxaliplatin-based chemotherapy+ bevacizumab as first-line treatment for advanced colorectal cancer. Am. J. Clin. Oncol. 2015;38:227-233. [DOI:10.1097/COC.0b013e3182a2d7b8] [PMID]
26. Ibrahim A., Hirschfeld S., Cohen M.H., Griebel D.J., Williams G.A., Pazdur R. FDA drug approval summaries: Oxaliplatin. Oncologist. 2004;9:8-12. doi: 10.1634/theoncologist.9-1-8. [DOI:10.1634/theoncologist.9-1-8] [PMID]
27. Zhu L., Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell. Mol. Biol. Lett. 2019;24:40. doi: 10.1186/s11658-019-0164-y. [DOI:10.1186/s11658-019-0164-y] [PMID] []
28. Semrad T.J., Fahrni A.R., Gong I.Y., Khatri V.P. Integrating chemotherapy into the management of oligometastatic colorectal cancer: Evidence-based approach using clinical trial findings. Ann. Surg. Oncol. 2015;22:855-862. doi: 10.1245/s10434-015-4610-4. [DOI:10.1245/s10434-015-4610-4] [PMID] []
29. Ahmed F., Kumari S., Kondapi A.K. Evaluation of antiproliferative activity, safety and biodistribution of oxaliplatin and 5-fluorouracil loaded lactoferrin nanoparticles for the management of colon adenocarcinoma: An in vitro and an in vivo study. Pharm. Res. 2018;35:178. [DOI:10.1007/s11095-018-2457-7] [PMID]
30. Zhou J., Chang L., Guan Y., Yang L., Xia X., Cui L., Yi X., Lin G. Application of circulating tumor DNA as a non-invasive tool for monitoring the progression of colorectal cancer. PLoS ONE. 2016;11:e0159708. doi: 10.1371/journal.pone.0159708. [DOI:10.1371/journal.pone.0159708] [PMID] []
31. Lv C., Qu H., Zhu W., Xu K., Xu A., Jia B., Qing Y., Li H., Wei H.-J., Zhao H.-Y. Low-dose paclitaxel inhibits tumor cell growth by regulating glutaminolysis in colorectal carcinoma cells. Front. Pharmacol. 2017;8:244. doi: 10.3389/fphar.2017.00244. [DOI:10.3389/fphar.2017.00244] [PMID] []
32. Einzig A.I., Neuberg D., Wiernik P.H., Grochow L.B., Ramirez G., O'Dwyer P.J., Petrelli N.J. Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An eastern cooperative oncology group trial (PA286) Am. J. Ther. 1996;3:750-754. [DOI:10.1097/00045391-199611000-00003] [PMID]
33. Laraib U., Sargazi S., Rahdar A., Khatami M., Pandey S. Nanotechnology-based approaches for effective detection of tumor markers: A comprehensive state-of-the-art review. Int. J. Biol. Macromol. 2021;195:356-383 [DOI:10.1016/j.ijbiomac.2021.12.052] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
